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Nested variants of urothelial carcinoma are 
characterized by deceptively bland histomorphology and 
aggressive clinical behavior. Previously, TERT promoter 
mutation has been described as specific molecular 
finding for Nested Variants of Urothelial Carcinoma 
(NVUC). But to date, no good reliable IHC markers have 
been discovered to differentiate benign mimickers of 
NVUC including Von Brunn's Nests (VBN) from NVUC. 
Recently, loss of FBP1 has been found to be associated 
with several high grade tumors and may be responsible 
for Warburg effect at molecular level (Nature, 513:251-
5). Fructose-1, 6-bisphosphate is intermediate in 
glycolysis and its level is mainly controlled by 
upregulation of fructose-6-phosphate kinase and 
downregulation of FBP-1. Here, we would like to 
evaluate the potential role of FBP1 IHC stain to 
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Tissue microarray slides (TMA) were constructed from 
141 cases of UC, including 97 high grade (HG) and 44 
low-grade (LG) cases.  
We also retrieved Nested (21) and Large Nested (5) 
variants of urothelial carcinoma from two institutes. The 
TMA slides and full section slides were subjected to 
IHC stain for FBP1 (Sigma, 1:100 dilutions). The 
morphology and FBP-1 staining intensity of urothelial 
component were carefully examined. 
 
3. Decrease expression or loss of FBP-1 was noticed  in       
   19/21 (90%) NVUC and 4/5 (80%) of LNVUC (non-     




1) Loss of FBP1is associated with UC and especially 
high grade UC.  
2) Loss of FBP-1 can be used as a diagnostic marker to 
differentiate NVUC from other benign entities 
including VBN. 
3) Down-regulation of FBP1 may be one of the               
mechanisms of urothelial carcinoma to gain cancer 
cell proliferation and tumourigenicity. It may be 
potential target for novel therapy. 
 
REFRENCES: 
A) H&E of LNVUC  B) FBP-1 in LNVUC  
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1. Normal urothelium are strongly positive for FBP1. 
2. Among 141 case of UC from TMA, 79% HG UC and     
56% LG UC had decrease or loss of FBP1.  
